{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:14:45Z","timestamp":1760192085437,"version":"build-2065373602"},"reference-count":84,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AOUC (Azienda Ospedaliera Universitaria Careggi) Florence","award":["AOUC ric.41 \u2013 2011"],"award-info":[{"award-number":["AOUC ric.41 \u2013 2011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxin (BoNT) can counteract the highly frequent involuntary muscle contractions and the uncontrolled micturition events that characterize the neurogenic detrusor overactivity (NDO) due to supra-sacral spinal cord lesions. The ability of the toxin to block the neurotransmitter vesicular release causes the reduction of contractions and improves the compliance of the muscle and the bladder filling. BoNT is the second-choice treatment for NDO once the anti-muscarinic drugs have lost their effects. However, the toxin shows a time-dependent efficacy reduction up to a complete loss of activity. The cellular mechanisms responsible for BoNT effects exhaustion are not yet completely defined. Similarly, also the sites of its action are still under identification. A growing amount of data suggest that BoNT, beyond the effects on the efferent terminals, would act on the sensory system recently described in the bladder mucosa. The specimens from NDO patients no longer responding to BoNT treatment displayed a significant increase of the afferent terminals, likely excitatory, and signs of a chronic neurogenic inflammation in the mucosa. In summary, beyond the undoubted benefits in ameliorating the NDO symptomatology, BoNT treatment might bring to alterations in the bladder sensory system able to shorten its own effectiveness.<\/jats:p>","DOI":"10.3390\/toxins11110614","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T04:41:27Z","timestamp":1571978487000},"page":"614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin"],"prefix":"10.3390","volume":"11","author":[{"given":"Chiara","family":"Traini","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Research Unit of Histology and Embryology, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuliana","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Research Unit of Histology and Embryology, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins"},{"key":"ref_2","first-page":"198","article-title":"AAN Updates Guidelines on the Uses of Botulinum Neurotoxin","volume":"95","author":"Wilkes","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.gaitpost.2018.02.014","article-title":"Long-term gait outcomes following conservative management of idiopathic toe walking","volume":"62","author":"Davies","year":"2018","journal-title":"Gait Posture"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Niemann, N., and Jankovic, J. (2018). Botulinum Toxin for the Treatment of Hand Tremor. Toxins, 10.","DOI":"10.3390\/toxins10070299"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Park, J., and Chung, M.E. (2018). Botulinum Toxin for Central Neuropathic Pain. Toxins, 10.","DOI":"10.3390\/toxins10060224"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/DSS.0000000000001878","article-title":"A Systematic Review of Patient-Reported Outcomes for Cosmetic Indications of Botulinum Toxin Treatment","volume":"45","author":"Wang","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Weise, D., Weise, C.M., and Naumann, M. (2019). Central Effects of Botulinum Neurotoxin\u2014Evidence from Human Studies. Toxins, 11.","DOI":"10.3390\/toxins11010021"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00345-018-2301-z","article-title":"Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury","volume":"36","author":"Hamid","year":"2018","journal-title":"World J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/003591577206500244","article-title":"Motor nerve growth induced by botulinum toxin as a regenerative phenomenon","volume":"65","author":"Duchen","year":"1972","journal-title":"Proc. Roy. Soc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1113\/jphysiol.2008.153569","article-title":"Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin Am","volume":"586","author":"Rogozhin","year":"2008","journal-title":"J. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","article-title":"More Than 15 Years of Experience with Intradetrusor Onabotulinumtoxin A Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned","volume":"70","author":"Leitner","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/B978-0-444-63247-0.00005-5","article-title":"Anatomy and physiology of the lower urinary tract","volume":"130","author":"Yoshimura","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MOU.0b013e3283476ea2","article-title":"The afferent system and its role in lower urinary tract dysfunction","volume":"21","author":"Daly","year":"2011","journal-title":"Curr. Opin. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/nau.22465","article-title":"Lamina propria: The functional center of the bladder?","volume":"33","author":"Andersson","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/nau.22635","article-title":"Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of \u201cOveractive bladder\u201d","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bcpt.12626","article-title":"The Role of the Mucosa in Normal and Abnormal Bladder Function","volume":"119","author":"Fry","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.aanat.2018.01.009","article-title":"The telocytes\/myofibroblasts 3-D network forms a stretch receptor in the human bladder mucosa. Is this structure involved in the detrusor overactive diseases?","volume":"218","author":"Vannucchi","year":"2018","journal-title":"Ann. Anat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/nau.22839","article-title":"Implications for bidirectional signaling between afferent nerves and urothelial cells-ICI-RS 2014","volume":"35","author":"Kanai","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1113\/jphysiol.2014.283119","article-title":"Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder","volume":"593","author":"Beckel","year":"2015","journal-title":"J. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bju.12954","article-title":"ATP release from freshly isolated guinea-pig bladder urothelial cells: A quantification and study of the mechanisms involved","volume":"115","author":"McLatchie","year":"2015","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/nau.22508","article-title":"Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium","volume":"34","author":"Barrick","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuint.2005.04.021","article-title":"Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A","volume":"47","author":"Smith","year":"2005","journal-title":"Neurochem. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuint.2007.11.006","article-title":"Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury","volume":"52","author":"Smith","year":"2008","journal-title":"Neurochem. Int."},{"key":"ref_27","first-page":"F226","article-title":"Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder","volume":"275","author":"Birder","year":"1998","journal-title":"Am. J. Physiol.."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1523\/JNEUROSCI.22-18-08063.2002","article-title":"Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder and urothelial cells","volume":"22","author":"Birder","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1464-410X.1987.tb04575.x","article-title":"Eicosanoid Synthesis by Human Urinary Bladder Mucosa: Pathological Implications","volume":"59","author":"Jeremy","year":"1987","journal-title":"BJU Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2220\/biomedres.29.105","article-title":"Urothelium EP1 receptor facilitates the micturition reflex in mice","volume":"29","author":"Wang","year":"2008","journal-title":"Biomed. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2009.08705.x","article-title":"Stretch independent regulation of prostaglandin E2production within the isolated guinea-pig lamina propria","volume":"105","author":"Nile","year":"2010","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.lfs.2007.02.010","article-title":"Non-neuronal acetylcholine and urinary bladder urothelium","volume":"80","author":"Beckel","year":"2007","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1111\/bph.12682","article-title":"Regulation of ACh release from guinea pig bladder urothelial cells: Potential role in bladder filling sensations","volume":"171","author":"McLatchie","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2012.03.031","article-title":"Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder","volume":"62","author":"Ikeda","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1464-410X.2003.03802.x","article-title":"The role of the human bladder lamina propria myofibroblast","volume":"91","author":"Wiseman","year":"2003","journal-title":"BJU Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/jcmm.12375","article-title":"Telocytes subtypes in human urinary bladder","volume":"18","author":"Vannucchi","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jcmm.13308","article-title":"Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity","volume":"22","author":"Traini","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0022-5347(17)32790-8","article-title":"Differential Release of Prostaglandins and Leukotrienes by Sensitized Guinea Pig Urinary Bladder Layers Upon Antigen Challenge","volume":"152","author":"Saban","year":"1994","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pmrj.2018.07.016","article-title":"A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder","volume":"11","author":"Cooley","year":"2019","journal-title":"PM R"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1464-410X.2006.06395.x","article-title":"The management of neurogenic bladder and quality of life in spinal cord injury","volume":"98","author":"Ku","year":"2006","journal-title":"BJU Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1089\/neu.2011.2226","article-title":"The health and life priorities of individuals with spinal cord injury: A systematic review","volume":"29","author":"Simpson","year":"2012","journal-title":"J. Neurotrauma"},{"key":"ref_42","first-page":"127","article-title":"Detrusor sphincter dyssynergia: A review of physiology, diagnosis, and treatment strategies","volume":"5","author":"Stoffel","year":"2016","journal-title":"Transl. Androl. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2006.11.016","article-title":"Human Idiopathic and Neurogenic Overactive Bladders and the Role of M2 Muscarinic Receptors in Contraction","volume":"52","author":"Stevens","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sc.2013.19","article-title":"Neurogenic detrusor overactivity in adults: A review on efficacy, tolerability and safety of oral antimuscarinics","volume":"51","author":"Madersbacher","year":"2013","journal-title":"Spinal Cord"},{"key":"ref_45","first-page":"6650","article-title":"Intradetrusorial onabotulinum toxin A injection: How to do it","volume":"20","author":"Shenot","year":"2013","journal-title":"Can. J. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Moore, D.C., Cohn, J.A., and Dmochowski, R.R. (2016). Use of botulinum toxin A in the treatment of lower urinary tract disorders: A review of the litteraure. Toxins, 8.","DOI":"10.3390\/toxins8040088"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment","volume":"196","author":"Rovner","year":"2016","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1590\/s1677-5538.ibju.2016.0584","article-title":"Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury","volume":"43","author":"Lombardi","year":"2017","journal-title":"Int. Braz. J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1464-410X.2005.05368_7.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"95","author":"Knispel","year":"2005","journal-title":"BJU Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1002\/nau.23552","article-title":"What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder\/detrusor overactivity? ICI-RS 2017","volume":"37","author":"Malde","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","article-title":"Effect of Botulinum Toxin A on the Autonomic Nervous System of the Rat Lower Urinary Tract","volume":"169","author":"Smith","year":"2003","journal-title":"J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apha.12012","article-title":"Purinergic signaling in the lower urinary tract","volume":"207","author":"Burnstock","year":"2013","journal-title":"Acta Phisiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","article-title":"Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation","volume":"101","author":"Lucioni","year":"2008","journal-title":"BJU Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1469-445X.1999.tb00078.x","article-title":"The activation of bladder wall afferent nerves","volume":"84","author":"Morrison","year":"1999","journal-title":"Exp. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ncpuro1124","article-title":"Drug Insight: Biological effects of botulinum toxin A in the lower urinary tract","volume":"5","author":"Chancellor","year":"2008","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.ju.0000143189.19835.f3","article-title":"Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation","volume":"173","author":"Vemulakonda","year":"2005","journal-title":"J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","article-title":"Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity","volume":"279","year":"2004","journal-title":"J. Boil. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased Sensory Receptors P2x 3 And Trpv1 In Suburothelial Nerve Fibers Following Intradetrusor Injections Of Botulinum Toxin For Human Detrusor Overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/nau.22634","article-title":"Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A","volume":"33","author":"Dolly","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1254\/jphs.FM0070115","article-title":"Basic and clinical aspects of non-neuronal acetylcholine: Expression of non-neuronal acetylcholine in urothelium and its clinical significance","volume":"106","author":"Yoshida","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bju.12266","article-title":"OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium","volume":"112","author":"Collins","year":"2013","journal-title":"BJU Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem. Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/bmc-2014-0029","article-title":"Telocytes revisited","volume":"5","author":"Cretoiu","year":"2014","journal-title":"Biomol. Concepts"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1464-410X.2004.05186.x","article-title":"cGMP-generating cellsin the bladder wall: Identification of distinct networks of interstitial cells","volume":"94","author":"Gillespie","year":"2004","journal-title":"BJU Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0022-5347(05)64910-5","article-title":"Topography of the Vanilloid Receptor in the Human Bladder: More Than Just the Nerve Fibers","volume":"168","author":"Ost","year":"2002","journal-title":"J. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(06)00563-5","article-title":"Localization of M2 and M3 muscarinic receptors in human bladderdisorders and their clinical correlations","volume":"176","author":"Mukerji","year":"2006","journal-title":"J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Svennersten, K., Hall\u00e9n-Grufman, K., De Verdier, P.J., Wiklund, N.P., and Poljakovic, M. (2015). Localization of P2X receptor subtypes 2, 3 and 7 in human urinary bladder. BMC Urol., 15.","DOI":"10.1186\/s12894-015-0075-9"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1113\/jphysiol.2004.067934","article-title":"Purinergic regulation of guinea pig suburothelial myofibroblasts","volume":"559","author":"Wu","year":"2004","journal-title":"J. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"F688","DOI":"10.1152\/ajprenal.00133.2008","article-title":"Modulation of bladder myofibroblast activity: Implications for bladder function","volume":"295","author":"Sui","year":"2008","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-27592-5_3","article-title":"Enteric Inhibitory Neurotransmission, Starting Down Under","volume":"891","author":"Sanders","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum Toxin: Mechanisms of Action","volume":"53","author":"Saberi","year":"2005","journal-title":"Eur. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2006.01.025","article-title":"Histologic Features in the Urinary Bladder Wall Affected from Neurogenic Overactivity\u2014A Comparison of Inflammation, Oedema and Fibrosis With and Without Injection of Botulinum Toxin Type A","volume":"50","author":"Reitz","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2004.07.011","article-title":"Lack of Ultrastructural Detrusor Changes Following Endoscopic Injection of Botulinum Toxin Type A in Overactive Neurogenic Bladder","volume":"46","author":"Haferkamp","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1111\/jcmm.14294","article-title":"Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies","volume":"23","author":"Traini","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1464-410X.2003.04186.x","article-title":"Innervation of the detrusor muscle bundle in neurogenic detrusor overactivity","volume":"91","author":"Drake","year":"2003","journal-title":"BJU Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00281-018-0674-0","article-title":"Role of neurogenic inflammation in local communication in the visceral mucosa","volume":"40","author":"Birder","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"ref_81","unstructured":"Sant, G.R. (1997). Neurogenic inflammation and nerve growth factor: Possible roles in interstitial cystitis. Interstitial Cystitis, Lippincott-Raven."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00281-017-0669-2","article-title":"Origins of antidromic activity in sensory afferent fibers and neurogenic inflammation","volume":"40","author":"Sorkin","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00281-018-0675-z","article-title":"Skin neurogenic inflammation","volume":"40","author":"Choi","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/exd.12798","article-title":"Self-maintenance of neurogenic inflammation contributes to a vicious cycle in skin","volume":"24","author":"Gouin","year":"2015","journal-title":"Exp. Dermatol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/11\/614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:00Z","timestamp":1760189340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/11\/614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":84,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["toxins11110614"],"URL":"https:\/\/doi.org\/10.3390\/toxins11110614","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}